Replies to post #18886 on Secure Point Technologies Inc (fka IMSCQ)

[Doctor Detroit]

In any event, I think the rubber is going to meet the road on this one sooner rather than later. The fully diluted number I came up with (187.5 million) is getting dangerously close to the 200 million shares authorized. In fact, some of DMRJ's conversion activity may be in recognition of the fact that there is very little room left in the authorized share count allow for additional convertible debt to be incurred. $1.0 million more of interest on the 8 cent note (it's currently accruing about $825,000 a year in interest) would mean 12.5 million more convertible shares...taking the fully diluted number to 199.5 (without taking into account the other convertible debt). Simply put, Implant won't have the enough shares authorized to issue in the event of a conversion, and DMRJ doesn't want to be hanging in the wind holding convertible debt for which there are not shares available for issuance.

Implant can't increase that number without going to the stockholders for approval. Something they haven't done in quite some time, and which may not be approved. If you knew that was coming up, wouldn't you have filed a proxy statement by now? They haven't, and perhaps because they've come to the conclusion that it won't be necessary.

[Buzzlityr]

Doc D- can't say I know much about SBA loans but they are an arrow in the quiver.

I think a strategic buy in would be an option, but one that has to be large enough to extract dmrj out of the stock.

After that, its more dmrj like options, none of which are THAT much more attractive but anything is an improvement on the terms they hold over the stock.

A buy out now, well, the whole scenario says: lowball and not fully valued. So today, I dislike that option, if it is a lowball attempt. Drs. McGann and Jones have a card to play here as they are greatly incented to find that buy in entity.

I sure would have liked to see mgt. convert at 1.4 if the stock had reached 2.01 or there abouts, which aligns them more closely with common.

As I said, another product gets into tsa cert. process and the value goes thru the roof, imo so we might see a stopgap kind of deal to take out some debt, provide operating funds and allow them to get a product ready for data capture.

Doc- what do you see happening, if you had to boil out the giddy thinking, the hopeful ideas and deal with just reality come Jan. 15th-- note, I think your $3 take out is not real today.
Best of Better Luck to ALL IMSC LONGS!

[Doctor Detroit]

Not sure what to make of it all, but I like this...

"FDA will take a flexible, adaptive approach to the evaluation and labeling of abuse-deterrent opioid products"

[Doctor Detroit]

Hopefully they are done issuing warrants! I know in the Fall they were just "doing what they had to do" to keep the doors open, but it nets out to about 28% per share dilution as a result of the financing. TTNP went from being 99.5 million shares fully diluted, to about 137 million shares.

On the positive side, to get the common stock under the warrants they have to pay the exercise price. There are 5.4 million in 2012 Series A Warrants with an exercise price of $0.89...which would result in proceeds to TTNP of $4,806,000. There are 15.75 million in 2014 Class A Warrants with an exercise price of $0.60...which would result in proceeds of $9.45 million.

So along with the $15 million milestone payment upon Probuphine approval, TTNP could receive up to another $15 million if the warrants are all exercised.